Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK F1174L |
| Therapy | XMU-MP-5 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK F1174L | Advanced Solid Tumor | predicted - resistant | XMU-MP-5 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L did not demonstrate sensitivity to treatment with XMU-MP-5 in culture (PMID: 34845836). | 34845836 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34845836) | A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. | Full reference... |